http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H02231494-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f6e960aa6ad2ba6401030159343ebe68
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D519-04
filingDate 1989-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eed1a723dbcc46d3dd209b5c8155eb55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0c3ef64fda50cf25e9e10ab732da9dbf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_686c00fa0664990963c33689b0227ee3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_960949f176e2edeb0f2259ce2e1721f3
publicationDate 1990-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber JP-H02231494-A
titleOfInvention Production of dimer alkaloids
abstract PURPOSE: To obtain the title compound such as vinblastine having antitumor activity and useful as an anticancer agent by adding oxalic acid (salt), etc., inorganic anion source, trivalent iron source and hydride source to a specific compound used as a starting raw material in the presence of oxygen. n CONSTITUTION: Oxalic acid (salt) and/or malonic acid (salt), inorganic anion source (preferably Cl - , Br - , I - , SO, etc., except such an inorganic anion as to produce an insoluble iron salt such as CO), trivalent iron source (preferably hydrochloric acid salt, sulfuric acid salt or nitric acid salt) and hydride source (e.g. sodium borohydride) are added to a compound (e.g. anhydro-vinblastine) expressed by formula I (R 1 is H, lower alkyl or formyl; R 2 is lower alkoxycarbonyl or amide; R 3 is acetoxy or OH) and used as a starting raw material in the presence of oxygen to provide the aimed compound expressed by formula II (R 4 is OH and R 5 is Et or R 4 is Et and R 5 is OH). n COPYRIGHT: (C)1990,JPO&Japio
priorityDate 1989-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458392901
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID433323693
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11104750
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419535677
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID454306093
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426494055
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393647
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419523291
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID313
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID451404211
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID166653
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID867
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559594
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID971
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID124516887
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419557048
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419491185
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID412584819
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID152743287
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID977
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23925
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419474387
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1118
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID22959485
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4311764
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419474255
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID13342
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395766

Total number of triples: 41.